Clinical application of bone turnover markers in osteoporosis.

Autor:	Rand MS; Afdeling for Klinisk Biokemi, Københavns Universitetshospital - Rigshospitalet, Glostrup., Eiken PA; Endokrinologisk Afdeling, Københavns Universitetshospital - Bispebjerg Hospital., Jørgensen NR; Afdeling for Klinisk Biokemi, Københavns Universitetshospital - Rigshospitalet, Glostrup.; Institut for Klinisk Medicin, Københavns Universitet.
Jazyk:	dánština
Zdroj:	Ugeskrift for laeger [Ugeskr Laeger] 2024 Jan 29; Vol. 186 (5). Date of Electronic Publication: 2024 Jan 29.
DOI:	10.61409/V07230432
Abstrakt:	Bone turnover markers (BTM) are highly responsive to initiation and changes in anti-osteoporotic therapy. In contrast to the slow treatment-induced changes in bone mineral density, the fast changes in BTM enable the clinician to adjust treatment management within a short timeframe. This review describes how BTM can be used for treatment monitoring, including monitoring during discontinuation of alendronate and denosumab therapy. In addition, sources of errors and pitfalls when using BTM monitoring will be described. (Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu